Download PDF
Kinder- und Jugendmedizin 2021; 21(05): 329-338
DOI: 10.1055/a-1576-6451
Schwerpunkt

Therapie mit Januskinasehemmern bei Autoimmunerkrankungen und Interferonopathien

Januskinase inhibitor treatment in autoimmune diseases and interferonopathies
Ariane Klein∗
1   Kinderklinik Sankt Augustin, Sankt Augustin
2   Universität Köln, Abteilung Pädiatrie
› Author Affiliations
› Further Information
    Permissions and Reprints

ZUSAMMENFASSUNG

Eine neuere Entwicklung bei der Pharmakotherapie der Autoimmunerkrankungen sind die Janus-Kinase (JAK)-Inhibitoren (JAKI) und Aktivatoren der Transkription (STAT).

Der JAK/STAT-Signalweg und die damit verbundene Aktivierung des Transkription-Signalweges spielen offenbar eine zentrale Rolle in der Pathogenese vieler immunvermittelter Krankheiten, da die Wirkung vieler verschiedener Zytokine und anderer Moleküle hierüber vermittelt wird. JAKI wirken intrazellulär und können so gleichzeitig die Signalwege mehrerer Zytokine blockieren.

Während des letzten Jahrzehnts wurden mehrere JAKI, die eines oder mehrere der an diesem Signalweg beteiligten Moleküle blockieren, entwickelt und in klinischen Studien für viele verschiedene Indikationen getestet. Obwohl der Schwerpunkt der JAKI für die Behandlung chronisch entzündlicher Erkrankungen auf der rheumatoiden Arthritis (RA) lag, gibt es andere immunvermittelte Erkrankungen, bei denen JAKI als therapeutische Optionen dienen könnten. Hierzu zählen Psoriasis, atopische Dermatitis, Alopezia areata, chronisch entzündliche Darmerkrankungen, Interferonopathien und andere. Es soll hier ein Überblick über den Einsatz von JAKI bei immunvermittelten Erkrankungen abgesehen von der rheumatoiden Arthritis und der juvenilen idiopathischen Arthritis vermittelt werden.

ABSTRACT

A recent development in the pharmacotherapy of immun mediated diseases are Janus kinase (JAK) inhibitors (JAKI) and activators of transcription (STAT).

The JAK/STAT signaling pathway and the associated activation of the transcription signaling pathway appear to play a central role in the pathogenesis of many immune-mediated diseases, as the action of many different cytokines and other molecules is mediated through this pathway. JAKI can inhibit the signaling pathways of several cytokines and molecules simultaneously.

During the last decade, several JAKI that block one or more of the molecules involved in this pathway have been developed and tested in clinical trials for many different indications. Although the focus of JAKI for the treatment of chronic inflammatory diseases has been rheumatoid arthritis (RA), there are other immune-mediated diseases for which JAKI could serve as therapeutic options. These include psoriasis and other skin diseases such as atopic dermatitis or alopecia areata, inflammatory bowel diseases, interferonopathies, and others. An overview of the use JAKI in treatment of immune-mediated diseases apart from rheumatoid arthritis and juvenile idiopathic arthritis will be provided here.

Schlüsselwörter

Januskinaseinhibitor - Autoimmunerkrankung - Interferonopathie

Keywords

Januskinase inhibitor - autoimmune disease - interferonopathy


Publication History

Article published online:
18 October 2021

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG,
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?. Ann Rheum Dis 2018; 77 (02) 175-187
    CrossrefPubMedGoogle Scholar
  • 2 O’Shea JJ, Kontzias A, Yamaoka K. et al Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013; 72 (Suppl. 02) ii 111-115
    CrossrefPubMedGoogle Scholar
  • 3 Banerjee S, Biehl A, Gadina M. et al JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs 2017; 77 (05) 521-546
    CrossrefPubMedGoogle Scholar
  • 4 Schwartz DM, Kanno Y, Villarino A. et al JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017; 16 (12) 843-862
    CrossrefPubMedGoogle Scholar
  • 5 Arican O, Aral M, Sasmaz S. et al Serum levels of TNFalpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 5: 273-279
    CrossrefPubMedGoogle Scholar
  • 6 Raj D, Brash DE, Grossman D. Keratinocyte apoptosis in epidermal development and disease. J Invest Dermatol 2006; 126: 243-257
    CrossrefPubMedGoogle Scholar
  • 7 Wcisl o-Dziadecka D, Zbiciak-Nylec M, Brzezin skaWcisl o L. et al Newer treatments of psoriasis regarding IL23 inhibitors, phosphodiesterase 4 inhibitors, and Januskinase inhibitors. Dermatol Ther 2017; 30: e12555
    CrossrefPubMedGoogle Scholar
  • 8 Papp KA, Menter MA, Abe M. et al Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 2015; 173: 949-961
    CrossrefPubMedGoogle Scholar
  • 9 Papp KA, Krueger JG, Feldman SR. et al Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol 2016; 74: 841-850
    CrossrefPubMedGoogle Scholar
  • 10 Merola JF, Elewski B, Tatulych S. et al Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2017; 77: 79-87.e1
    CrossrefPubMedGoogle Scholar
  • 11 Bachelez H, van de Kerkhof PCM, Strohal R. et al Tofacitinib versus etanercept or placebo in moderate-tosevere chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 2015; 386: 552-561
    CrossrefPubMedGoogle Scholar
  • 12 Valenzuela F, Paul C, Mallbris L. et al Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study. J Eur Acad Dermatol Venereol 2016; 30: 1753-1759
    CrossrefPubMedGoogle Scholar
  • 13 Bissonnette R, Iversen L, Sofen H. et al Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol 2015; 172: 1395-1406
    CrossrefPubMedGoogle Scholar
  • 14 Papp KA, Bissonnette R, Gooderham M.. et al Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatol 2016; 16: 15 DOI: 10.1186/s12895-016-0051-4.
    CrossrefPubMedGoogle Scholar
  • 15 Papp KA, Menter MA, Raman M. et al A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol 2016; 174: 1266-1276
    CrossrefPubMedGoogle Scholar
  • 16 Papp K, Pariser D, Catlin M. et al A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderateto-severe psoriasis. Br J Dermatol 2015; 173: 767-776
    CrossrefPubMedGoogle Scholar
  • 17 Ludbrook VJ, Hicks KJ, Hanrott KE. et al Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. Br J Dermatol 2016; 174: 985-995
    CrossrefPubMedGoogle Scholar
  • 18 Schmieder GJ, Draelos ZD, Pariser DM. et al Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. Br J Dermatol 2018; 179: 54-62
    CrossrefPubMedGoogle Scholar
  • 19 Punwani N, Burn T, Scherle P. et al Downmodulation of key inflammatory cell markers with a topical Janus kinase ½ inhibitor. Br J Dermatol 2015; 173: 989-997
    CrossrefPubMedGoogle Scholar
  • 20 Punwani N, Scherle P, Flores R. et al Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 2012; 67: 658-664
    CrossrefPubMedGoogle Scholar
  • 21 Gilhar A, Schrum AG, Etzioni A. et al Alopecia areata: animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies. Autoimmun Rev 2016; 15: 726-735
    CrossrefPubMedGoogle Scholar
  • 22 Xing L, Dai Z, Jabbari A. et al Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014; 20: 1043-1049
    CrossrefPubMedGoogle Scholar
  • 23 Kennedy Crispin M, Ko JM, Craiglow BG. et al Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 2016; 01: e89776
    CrossrefPubMedGoogle Scholar
  • 24 Jabbari A, Sansaricq F, Cerise J. et al An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Invest Dermatol 2018; 138: 1539-1545
    CrossrefPubMedGoogle Scholar
  • 25 Liu LY, Craiglow BG, Dai F. et al Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 2017; 76: 22-28
    CrossrefPubMedGoogle Scholar
  • 26 Dhayalan A, King BA. Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis. JAMA Dermatol 2016; 152: 492-493
    CrossrefPubMedGoogle Scholar
  • 27 Liu LY, Craiglow BG, King BA. Tofacitinib 2 % ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol 2018; 78: 403-404.e1
    CrossrefPubMedGoogle Scholar
  • 28 Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol 2017; 76: 29-32
    CrossrefPubMedGoogle Scholar
  • 29 Mackay-Wiggan J, Jabbari A, Nguyen N. et al Oral ruxolitinib induces hair regrowth in patients with moderate-tosevere alopecia areata. JCI Insight 2016; 01: e89790
    CrossrefPubMedGoogle Scholar
  • 30 Craiglow BG, Tavares D, King BA. Topical ruxolitinib for the treatment of alopecia universalis. JAMA Dermatol 2016; 152: 490-491
    CrossrefPubMedGoogle Scholar
  • 31 Deeb M, Beach RA. A case of topical ruxolitinib treatment failure in alopecia areata. J Cutan Med Surg 2017; 21: 562-563
    CrossrefPubMedGoogle Scholar
  • 32 Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 2015; 73: 395-399
    CrossrefPubMedGoogle Scholar
  • 33 Bissonnette R, Papp KA, Poulin Y. et al Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 2016; 175: 902-911
    CrossrefPubMedGoogle Scholar
  • 34 Guttman-Yassky E, Silverberg JI, Nemoto O. et al Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. Journal of the American Academy of Dermatology 2019; 80 (04) 913-921.e9
    CrossrefPubMedGoogle Scholar
  • 35 Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 2017; 76: 736-744
    CrossrefPubMedGoogle Scholar
  • 36 Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol 2015; 151: 1110-1112
    CrossrefPubMedGoogle Scholar
  • 37 Harris JE, Rashighi M, Nguyen N. et al Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol 2016; 74: 370-371
    CrossrefPubMedGoogle Scholar
  • 38 Rothstein B, Joshipura D, Saraiya A. et al Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol 2017; 76: 1054-1060.e1
    CrossrefPubMedGoogle Scholar
  • 39 Sandborn WJ, Su C, Sands BE. et al OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2017; 376 (18) 1723-1736
    CrossrefPubMedGoogle Scholar
  • 40 Panes J, Vermeire S, Lindsay JO. et al Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies. J Crohns Colitis 2018; 12: 145-156
    CrossrefPubMedGoogle Scholar
  • 41 Sands BE, Sandborn WJ, Feagan BG. et al Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. J Crohns Colitis 2018; 09 12 (10) 1158-1169
    CrossrefPubMedGoogle Scholar
  • 42 Sandborn WJ, Ghosh S, Panes J. et al. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology 2020; 158 (08) 2139-2149.e14 DOI: 10.1053/j.gastro.2020.02.030. Epub 2020 Feb 22. Erratum in: Gastroenterology 2020; 159 (3): 1192
    CrossrefPubMedGoogle Scholar
  • 43 De Vries LCS, Wildenberg ME, De Jonge WJ. et al The future of Janus Kinase inhibitors in inflammatory bowel disease. J Crohns Colitis 2017; 11: 885-893
    CrossrefPubMedGoogle Scholar
  • 44 Kim DH, Cheon JH. Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune Netw 2017; 17: 25-40
    CrossrefPubMedGoogle Scholar
  • 45 Panés J, Sandborn WJ, Schreiber S. et al Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut 2017; 66 (06) 1049-1059
    CrossrefPubMedGoogle Scholar
  • 46 Vermeire S, Schreiber S, Petryka R. et al Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 2017; 389: 266-275
    CrossrefPubMedGoogle Scholar
  • 47 Sandborn WJ, Feagan BG, Panes J. et al Safety and efficacy of ABT-494 (Upadacitinib), an oral Jak1 Inhibitor, as induction therapy in patients with Crohn’s Disease: results from Celest. Gatroenterology 2017; 152: S1308-1309
    CrossrefGoogle Scholar
  • 48 Lee-Kirsch MA. The type I interferonopathies. Annu Rev Med 2017; 68: 297-315
    CrossrefPubMedGoogle Scholar
  • 49 Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014; 14: 36-49
    CrossrefPubMedGoogle Scholar
  • 50 Liu Y, Jesus AA, Marrero B. et al Activated STING in a vascular and pulmonary syndrome. N Engl J Med 2014; 371: 507-518
    CrossrefPubMedGoogle Scholar
  • 51 Fremond ML, Rodero MP, Jeremiah N. et al Efficacy of the Janus kinase ½ inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol 2016; 138: 1752-1755
    CrossrefPubMedGoogle Scholar
  • 52 König N, Fiehn C, Wolf C. et al Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis 2017; 76: 468-472
    CrossrefPubMedGoogle Scholar
  • 53 Wenzel J, van Holt N, Maier J. et al JAK1/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus. J Invest Dermatol 2016; 136: 1281-1283
    CrossrefPubMedGoogle Scholar
  • 54 Tüngler V, König N, Günther C. et al Response to: ‘JAK inhibition in STING-associated interferonopathy’ by Crow, et al. Ann Rheum Dis 2016; 75: e76
    CrossrefPubMedGoogle Scholar
  • 55 Kim H, Brooks KM, Tang CC. et al Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients. Clin Pharmacol Ther 2018; 104: 364-373
    CrossrefPubMedGoogle Scholar
  • 56 Sanchez GAM, Reinhardt A, Ramsey S. et al JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest 2018; 128 (07) 3041-3052
    CrossrefPubMedGoogle Scholar
  • 57 Huang J-F, Zhang Y, Hirakawa B. Evaluation of JAK inhibition with topical tofacitinib in an experimental autoimmune uveitis model (EAU). Invest Ophthalmol Vis Sci 2013; 54: 25-36
    CrossrefPubMedGoogle Scholar
  • 58 Paley MA, Karacal H, Rao PK. et al Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep 2019; 130: 53-55
    CrossrefPubMedGoogle Scholar
  • 59 Paley MA, Karacal H, Rao PK. et al Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep 2019; 130: 53-55
    CrossrefPubMedGoogle Scholar
  • 60 Miserocchi E, Giuffrè C, Cornalba M. et al JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol 2020; 39 (03) 847-851
    CrossrefPubMedGoogle Scholar
  • 61 Zhang H, Watanabe R, Berry GJ. et al Inhibition of JAKSTAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation 2018; 137: 1934-1948
    CrossrefPubMedGoogle Scholar
  • 62 Wallace DJ, Furie RA, Tanaka Y. et al Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018; 392 10143 222-231
    CrossrefPubMedGoogle Scholar
  • 63 Hornung T, Janzen V, Heidgen FJ. et al Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med 2014; 371: 2537-2538
    CrossrefPubMedGoogle Scholar
  • 64 Rimar D, Alpert A, Starosvetsky E. et al Tofacitinib for polyarteritis nodosa: a tailored therapy. Ann Rheum Dis 2016; 75: 2214-2216
    CrossrefPubMedGoogle Scholar
  • 65 Sin JH, Zangardi ML. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report. Hematol Oncol Stem Cell Ther 2019; 12 (03) 166-170
    CrossrefPubMedGoogle Scholar
  • 66 Winthrop KL, Citera G, Gold D. et al Age-based < 65 vs ≥ 65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry. Ann Rheum Dis 2021; 80 (01) 134-136
    CrossrefPubMedGoogle Scholar
  • 67 Kerschbaumer A, Smolen JS, Nash P. et al Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open 2020; 06 (03) e001374 DOI: 10.1136/rmdopen-2020-001374.
    CrossrefPubMedGoogle Scholar
  • 68 Nash P, Kerschbaumer A, Dörner T. et al Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021; 80 (01) 71-87
    CrossrefPubMedGoogle Scholar